



Press Release

**Change of name and stock symbol/mnemonic
of ABIONYX Pharma shares (formerly CERENIS Therapeutics)
as of August 29, 2019**

Toulouse, FRANCE, Lakeland, UNITED-STATES, August 27, 2019, 6:30pm CEST – Following the Extraordinary General Meeting of 21 June 2019, the shareholders of CERENIS Therapeutics approved the proposal for a new company name, which is now ABIONYX Pharma.

Beginning on 29 August 2019, the name, ISIN code and symbol/mnemonic of the share listed on Euronext Paris will be as follows:

- Share name: **ABIONYX Pharma** (replacing CERENIS Therapeutics)
- ISIN code of the share: **FR0012616852** (unchanged)
- Stock symbol / Mnemonic code of the action: **ABNX** (replacing CEREN).

ABIONYX Pharma is a new generation biotech company that seeks to leverage a rich portfolio of clinical and preclinical programs inherited from the assets of CERENIS Therapeutics, to focus on the discovery and development of innovative therapies.

About ABIONYX Pharma:

ABIONYX Pharma is a new biotech company dedicated to the discovery and development of innovative therapies for patients. The biotech assets from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as a HDL targeted drug delivery platform in oncology, more specifically in immuno-oncology and chemotherapy, as well as molecules targeted for other indications.

Contacts:

NewCap

Investor relations
Louis-Victor Delouvrier
abionyx@newcap.eu
+33 (0)1 44 71 98 53

NewCap

Media relations
Nicolas Merigeau
abionyx@newcap.eu
+33 (0)1 44 71 94 98

